Genetesis ^Partner

Genetesis is a clinical-stage medical device company dedicated to advancing cardiac imaging through biomagnetic technologies. Founded in 2013 by a group of friends from Ohio State University, the company is based in Buffalo, New York, and has grown to a team of over 20 employees with $40 million in funding as of 2023.

The company specializes in CardioFlux MCG, a non-invasive magnetocardiography system that detects coronary artery disease by measuring the heart’s magnetic field. This innovative technology aims to replace traditional radiation-based imaging methods, providing a safer and more efficient diagnostic tool. CardioFlux has received FDA Breakthrough Device designation, highlighting its potential to meet critical clinical needs. Genetesis targets hospitals and cardiology clinics, focusing on enhancing patient care through advanced imaging solutions.